DOCSLIB.ORG

Analysis of Fasl and TRAIL Induced Apoptosis Pathways in Glioma Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Analysis of Fasl and TRAIL Induced Apoptosis Pathways in Glioma Cells Oncogene (2001) 20, 5789 ± 5798 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells Melissa J Knight1,2,3,4, Christopher D Rikin1,2,3, Andrea M Muscat1,2,3, David M Ashley1,2,3 and Christine J Hawkins*,1,2,3 1Department of Haematology and Oncology, Royal Children's Hospital, Parkville, Australia; 2Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia; 3Department of Paediatrics, University of Melbourne, Parkville, Australia; 4Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia FasL and TNF-related apoptosis-inducing ligand therapies which induce apoptosis, such as radio- and (TRAIL) belong to a subgroup of the TNF superfamily chemotherapy. This study focuses on the death which induce apoptosis by binding to their death domain receptor mediated apoptotic pathways in glioma cells, containing receptors. In the present study we have induced by FasL (CD95L/Apo1L) and Tumor Necrosis utilized a panel of seven cell lines derived from human Factor-related apoptosis-inducing ligand (TRAIL/ malignant gliomas to characterize molecular pathways Apo2L). through which FasL and TRAIL induce apoptosis in FasL and TRAIL belong to a subgroup of the sensitive glioma cells and the mechanisms of resistance in Tumor Necrosis Factor (TNF) superfamily with the cell lines which survive the death stimuli. Our ®ndings unique ability to induce apoptosis. They do so via their indicate that FADD and Caspase-8 are essential for cognate death receptors Fas and DR4 (TRAIL-R1)/ FasL and TRAIL mediated apoptosis in glioma cells. DR5 (TRAIL-R2/Trick2) respectively, which are One sensitive cell line (D270) can be protected from characterized by a cytoplasmic death domain (reviewed FasL and TRAIL induced death by anti-apoptotic Bcl-2 by Reed, 2000). FasL and TRAIL can also bind to family members while another (D645) cannot, implying antagonist `decoy' receptors. DcR3/TR6/M68 is a that these lines may represent glioma examples of type II secreted soluble Fas decoy receptor which competes and type I cells respectively. For the ®rst time we with Fas for binding to FasL (Bai et al., 2000; Pitti et demonstrate resistance to FasL but not to TRAIL within al., 1998; Yu et al., 1999). Alternative splicing of the the one glioma cell line. Furthermore, we report distinct Fas gene can also give rise to mRNAs encoding mechanisms of resistance within dierent glioma lines, membrane bound proteins which lack the death including downregulation of Caspase-8 in U373MG. domain, such as the Fas Decoy Receptor (FDR) Cycloheximide sensitized four of the resistant cell lines (Jenkins et al., 2000). TRAIL can bind to the decoy suggesting the presence of labile inhibitors. None of the receptors DcR1 (TRAIL-R3/Trid/Lit) and DcR2 known apoptosis inhibitors examined accounted for the (TRAIL-R4/TRUNDD) which lack the intracellular observed resistance, suggesting novel inhibitors may exist death domain and are therefore incapable of inducing in glioma cells. Oncogene (2001) 20, 5789 ± 5798. the apoptotic pathway. TRAIL decoy receptors are expressed almost exclusively in normal cells (reviewed Keywords: apoptosis; glioma; resistance; TRAIL; Fas; by Reed 2000). Bcl-2 Studies in lymphoid cells suggest FasL and TRAIL engage similar apoptotic pathways in these cells. Aggregation of the death receptors by multimerized Introduction ligand induces the formation of a death-inducing signaling complex (DISC) (Kischkel et al., 1995; Sprick Malignant gliomas are the most frequent primary brain et al., 2000), involving the receptors' death domains tumors in adults and the prognosis of patients remains (DDs), the adaptor molecule FADD (Mort-1) and extremely poor (Hosli et al., 1998). Apoptosis is a Caspase-8 (FLICE, Mch5, MACH), which interact via highly evolutionarily conserved process fundamental to their death eector domains (DEDs). normal development and homeostasis. Defects in The subsequent activation of Caspase-8 at the Fas apoptosis regulation are implicated in a variety of DISC has been shown to propagate alternate apoptotic human diseases, including cancer (Reed, 1999). It is pathways (Scadi et al., 1998). In type I cells, active likely alterations in apoptotic pathways play a role in Caspase-8 directly cleaves downstream eector cas- the tumorigenesis of glioma and resistance to current pases, such as Caspase-3, which in turn cleave an array of substrates, leading to the systematic destruction of the cell (Wolf and Green, 1999). However in type II cells, DISC formation is less ecient and mitochon- *Correspondence: C Hawkins, Department of Haematology and drial ampli®cation of the death receptor induced signal Oncology, Royal Children's Hospital, Victoria Australia 3052; E-mail: [email protected] is required for apoptosis (Scadi et al., 1999b). Active Received 8 May 2001; revised 22 June 2001; accepted 5 July 2001 Caspase-8 cleaves the BH3-only Bcl-2 family member FasL and TRAIL induced apoptosis in glioma MJ Knight et al 5790 Bid and truncated Bid (tBID) translocates to the were sensitive to FasL, with the remainder being FasL mitochondria (Li et al., 1998). This results in the resistant (Figure 1a,b). D645 was also very sensitive to release of cytochrome-c, which binds to Apaf-1 and TRAIL induced apoptosis. U118MG, D270 and recruits Caspase-9 to form the `apoptosome' (Luo et U87MG displayed partial sensitivity to TRAIL, while al., 1998; Zou et al., 1999). This complex is involved in U251MG and U373MG were resistant (Figure 1d,e). the `intrinsic' apoptotic pathway, which is triggered by D54 was completely resistant to FasL, but sensitive to serum withdrawal (Zhang et al., 2000b) and DNA TRAIL. Death receptor mediated apoptosis has been damage (Coultas and Strasser, 2000). The Bcl-2 protein shown to converge downstream with the `intrinsic' family regulates apoptotic signals involving the apoptotic pathway which can be induced by che- mitochondria (reviewed by Gross et al., 1999). motherapy drugs. To examine sensitivity to such an Seven glioma cell lines were used in this study and apoptotic stimulus, cells were treated with the initially characterized for their sensitivity to FasL, chemotherapeutic agent cisplatin (Figure 1g,h). D270 TRAIL and cisplatin. The death receptor apoptotic was particularly sensitive to cisplatin with a second signal transduction pathways used by sensitive cells line, U118MG displaying intermediate sensitivity. and the mechanisms employed by resistant cells to D645, the most sensitive cell line to FasL and TRAIL, elude apoptosis were investigated. was resistant to cisplatin. U373MG and U251MG were resistant to all three death stimuli. Results Caspase-3 activity correlates with sensitivity Apoptosis triggered by all three agents studied has Glioma cell lines differ in their susceptibility to death been demonstrated in other cell types to involve stimuli activation of caspases. The tetrapeptide DEVD is A panel of seven glioma cell lines was characterized for cleaved by eector caspases such as Caspase-3. FasL and TRAIL sensitivity (refer to Table 1 and Cleavage of the ¯uorogenic substrate DEVD-AMC Discussion) using the sensitive lymphoid cell line was used to quantify activated Caspase-3 (and similar Jurkat as a control. Two distinct methods were used caspases) in each of the cell lines following treatment to assess cell viability with comparable results. The with FasL and TRAIL. Figure 1c,f demonstrate that glioma cell lines displayed dierential sensitivity to the amount of Caspase-3-like activity correlates with each of the death stimuli. D645, D270 and U118MG the susceptibility of the cells to apoptosis. Absolute Table 1 Summary of glioma cell line characteristics and apoptotic pathway analysis DISC Bcl-2 family Type I or Tumor components proteinsa Sensitivity Sensitized by Type IIb Proposed death receptor type Sex Age (Figure 3a) (Figure 3b) (Figure 1) CHX (Figure 5) (Figure 4) resistance mechanism U118 Anaplastic M 50 Intact F, High 3 May express low levels glioma T, Intermediate 3 of labile FasL and C, Intermediate x TRAIL inhibitor U251 Glioblastoma M 75 Intact Low Bcl-2 F, Resistant x Mutated component or multiforme T, Resistant x inhibitor with long C, Resistant x half-life U87 Glioblastoma F 44 Intact Low Bid F, Intermediate 3 May express low levels multiforme Low Bcl-xL T, Intermediate 3 of labile FasL and C, Low x TRAIL inhibitor U373 Glioblastoma M 50 Low levels F, Resistant x Low levels of multiforme FADD and T, Resistant x Caspase-8 Caspase-8 C, Resistant x D54 Mixed F 36 Intact High Bid F, Resistant 3 Fas specific labile anaplastic Low Bcl-2 T, High upstream inhibitor glioma C, Resistant x D270 Glioblastoma M 42 Intact High Bid F, High 3 Type II May express low levels multiforme High Bad T, Intermediate 3 of labile TRAIL Low Bcl-xL C, High x inhibitor D645 Glioblastoma F 10 Intact F, High Type I multiforme T, High C, Resistant x F=FasL, T=TRAIL, C=Cisplatin. aChange from the average only. bType I: inhibited by FADD DN and CrmA, Type II: inhibited by FADD DN, CrmA, Bcl-2 and Bcl-xL Oncogene FasL and TRAIL induced apoptosis in glioma MJ Knight et al 5791 Figure 1 Analysis of FasL (a,b,c), F-LZ-TRAIL (d,e,f) and cisplatin (g,h,i) induced apoptosis in the glioma line panel. Glioma cell lines were treated with TRAIL, FasL or control medium for 24 h (a,b,d,e)or6h(c,f) and 10 mg/ml cisplatin for 24 h (g,h)or12h (i). (a,d,g) Cell viability was assessed by colorimetric MTT assay. (b,e,h) Membrane integrity was measured by propidium iodide uptake. The data are expressed as percentage of viability relative to the cells exposed to the control media. Graphs represent the average and standard deviation of three individual experiments.
Load more

Recommended publications
  • (CS-ⅣA-Be), a Novel IL-6R Antagonist, Inhibits IL-6/STAT3
    Author Manuscript Published OnlineFirst on February 29, 2016; DOI: 10.1158/1535-7163.MCT-15-0551 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Chikusetsusaponin Ⅳa butyl ester (CS-Ⅳa-Be), a novel IL-6R antagonist, inhibits IL-6/STAT3 signaling pathway and induces cancer cell apoptosis Jie Yang 1, 2, Shihui Qian 2, Xueting Cai 1, 2, Wuguang Lu 1, 2, Chunping Hu 1, 2, * Xiaoyan Sun1, 2, Yang Yang1, 2, Qiang Yu 3, S. Paul Gao 4, Peng Cao 1, 2 1. Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China 2. Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, China 3. Shanghai Institute of Materia Medical, Chinese Academy of Sciences, Shanghai, 201203, China 4. Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY10065, USA Running title: CS-Ⅳa-Be, a novel IL-6R antagonist, inhibits IL-6/STAT3 Keywords: Chikusetsusaponin Ⅳ a butyl ester (CS- Ⅳ a-Be), STAT3, IL-6R, antagonist, cancer Grant support: P. Cao received Jiangsu Province Funds for Distinguished Young Scientists (BK20140049) grant, J. Yang received National Natural Science Foundation of China (No. 81403151) grant, and X.Y. Sun received National Natural Science Foundation of China (No. 81202576) grant. Corresponding author: Peng Cao Institute: Laboratory of Cellular and Molecular Biology, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210028, Jiangsu, China Mailing address: 100#, Shizi Street, Hongshan Road, Nanjing, Jiangsu, China Tel: +86-25-85608666 Fax: +86-25-85608666 Email address: [email protected] The first co-authors: Jie Yang and Shihui Qian The authors disclose no potential conflicts of interest.
    [Show full text]
  • BCMA-Targeted Immunotherapy for Multiple Myeloma Bo Yu1, Tianbo Jiang2 and Delong Liu2*
    Yu et al. Journal of Hematology & Oncology (2020) 13:125 https://doi.org/10.1186/s13045-020-00962-7 REVIEW Open Access BCMA-targeted immunotherapy for multiple myeloma Bo Yu1, Tianbo Jiang2 and Delong Liu2* Abstract B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development. Keywords: B cell maturation antigen, BCMA, Belantamab mafodotin, CAR-T, Antibody-drug conjugate, Bispecific T cell engager Introduction B cell maturation antigen (BCMA) Recent advances in novel therapeutics such as prote- BCMA is encoded by a 2.92-kb TNFRSF17 gene located asome inhibitors (PI) and immunomodulatory drugs on the short arm of chromosome 16 (16p13.13) and (IMiD) have significantly improved the treatment out- composed of 3 exons separated by 2 introns (Fig. 1). comes in patients with multiple myeloma (MM) [1–8]. BCMA is a 184 amino acid and 20.2-kDa type III trans- However, most MM patients eventually relapse due to membrane glycoprotein, with the extracellular N the development of drug resistance [9]. In addition, terminus containing a conserved motif of 6 cysteines many of the current popular target antigens, such as [18–21].
    [Show full text]
  • Snapshot: Cytokines III Cristina M
    SnapShot: Cytokines III Cristina M. Tato and Daniel J. Cua Schering-Plough Biopharma (Formerly DNAX Research), Palo Alto, CA 94304, USA Cytokine Receptor Source Targets Major Function Disease Association TNFα Murine: Macrophages, Neutrophils, Inflammatory; ↓ = disregulated fever; increased TNFR,p55; TNFR,p75 monocytes, T cells, macrophages, promotes activation susceptibility to bacterial infection; others monocytes, and production of enhanced resistance to LPS-induced septic Human: endothelial cells acute-phase proteins shock TNFR,p60; TNFR,p80 ↑ = exacerbation of arthritis and colitis LTα Murine: T cells, B cells Many cell types Promotes activation ↓ = defective response to bacterial TNFR,p55; TNFR,p75 and cytotoxicity; pathogens; absence of peripheral lymph development of lymph nodes and Peyer’s patches Human: nodes and Peyer’s TNFR,p60; TNFR,p80 patches LTβ LTβR T cells, B cells Myeloid cells, other Peripheral lymph ↓ = increased susceptibility to bacterial cell types node development; infection; absence of lymph nodes and proinflammatory Peyer’s patches ↑ = ectopic lymph node formation LIGHTa LTβR, DcR3, HVEM Activated T cells, B cells, NK cells, Costimulatory; ↓ = defective CD8 T cell costimulation monocytes, DCs DCs, other tissue promotes CTL activity TWEAK Fn14 Monocytes, Tissue progenitors, Proinflammatory; macrophages, epithelial, promotes cell growth endothelial endothelial for tissue repair and remodeling APRIL TACI, BAFF-R, BCMA Macrophages, DCs B cell subsets Promotes T cell- ↓ = impaired class switching to IgA independent
    [Show full text]
  • Tumor Invasion in Draining Lymph Nodes Is Associated with Treg Accumulation in Breast Cancer Patients
    ARTICLE https://doi.org/10.1038/s41467-020-17046-2 OPEN Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients Nicolas Gonzalo Núñez 1,7,9, Jimena Tosello Boari 1,9, Rodrigo Nalio Ramos 1, Wilfrid Richer1, Nicolas Cagnard2, Cyrill Dimitri Anderfuhren 3, Leticia Laura Niborski1, Jeremy Bigot1, Didier Meseure4,5, Philippe De La Rochere1, Maud Milder4,5, Sophie Viel1, Delphine Loirat1,5,6, Louis Pérol1, Anne Vincent-Salomon4,5, Xavier Sastre-Garau4,8, Becher Burkhard 3, Christine Sedlik 1,5, ✉ Olivier Lantz 1,4,5, Sebastian Amigorena1,5 & Eliane Piaggio 1,5 1234567890():,; Tumor-draining lymph node (TDLN) invasion by metastatic cells in breast cancer correlates with poor prognosis and is associated with local immunosuppression, which can be partly mediated by regulatory T cells (Tregs). Here, we study Tregs from matched tumor-invaded and non-invaded TDLNs, and breast tumors. We observe that Treg frequencies increase with nodal invasion, and that Tregs express higher levels of co-inhibitory/stimulatory receptors than effector cells. Also, while Tregs show conserved suppressive function in TDLN and tumor, conventional T cells (Tconvs) in TDLNs proliferate and produce Th1-inflammatory cytokines, but are dysfunctional in the tumor. We describe a common transcriptomic sig- nature shared by Tregs from tumors and nodes, including CD80, which is significantly associated with poor patient survival. TCR RNA-sequencing analysis indicates trafficking between TDLNs and tumors and ongoing Tconv/Treg conversion. Overall, TDLN Tregs are functional and express a distinct pattern of druggable co-receptors, highlighting their potential as targets for cancer immunotherapy.
    [Show full text]
  • Direct Estimation of Differential Networks
    Biometrika (2013), xx, x, pp. 1–16 C 2013 Biometrika Trust Advance Access publication on dd mm year Printed in Great Britain Direct estimation of differential networks BY SIHAI DAVE ZHAO Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA [email protected] 5 T. TONY CAI Department of Statistics, The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA [email protected] HONGZHE LI 10 Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania 19104, USA [email protected] SUMMARY It is often of interest to understand how the structure of a genetic network differs between 15 two conditions. In this paper, each condition-specific network is modeled using the precision matrix of a multivariate normal random vector, and a method is proposed to directly estimate the difference of the precision matrices. In contrast to other approaches, such as separate or joint estimation of the individual matrices, direct estimation does not require those matrices to be sparse, and thus can allow the individual networks to contain hub nodes. Under the assumption 20 that the true differential network is sparse, the direct estimator is shown to be consistent in support recovery and estimation. It is also shown to outperform existing methods in simulations, and its properties are illustrated on gene expression data from late-stage ovarian cancer patients. Some key words: Differential network; Graphical model; High dimensionality; Precision matrix 1. INTRODUCTION 25 A complete understanding of the molecular basis of disease will require characterization of the network of interdependencies between genetic components.
    [Show full text]
  • A Soluble Form of B Cell Maturation Antigen, a Receptor for the Tumor Necrosis Factor Family Member APRIL, Inhibits Tumor Cell Growth
    Brief Definitive Report A Soluble Form of B Cell Maturation Antigen, a Receptor for the Tumor Necrosis Factor Family Member APRIL, Inhibits Tumor Cell Growth By Paul Rennert,‡ Pascal Schneider,* Teresa G. Cachero,‡ Jeffrey Thompson,‡ Luciana Trabach,‡ Sylvie Hertig,* Nils Holler,* Fang Qian,‡ Colleen Mullen,‡ Kathy Strauch,‡ Jeffrey L. Browning,‡ Christine Ambrose,‡ and Jürg Tschopp* From the *Institute of Biochemistry, BIL Biomedical Research Center, University of Lausanne, CH-1066 Epalinges, Switzerland; and the ‡Departments of Molecular Genetics, Immunology, Inflammation, Cell Biology, and Protein Engineering, Biogen, Incorporated, Cambridge, Massachusetts 02142 Abstract A proliferation-inducing ligand (APRIL) is a ligand of the tumor necrosis factor (TNF) family that stimulates tumor cell growth in vitro and in vivo. Expression of APRIL is highly upregu- lated in many tumors including colon and prostate carcinomas. Here we identify B cell matura- tion antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand (CAML) interactor (TACI), two predicted members of the TNF receptor family, as re- ceptors for APRIL. APRIL binds BCMA with higher affinity than TACI. A soluble form of BCMA, which inhibits the proliferative activity of APRIL in vitro, decreases tumor cell prolif- eration in nude mice. Growth of HT29 colon carcinoma cells is blocked when mice are treated once per week with the soluble receptor. These results suggest an important role for APRIL in tumorigenesis and point towards a novel anticancer strategy. Key words: tumor necrosis factor • tumorigenesis • cell survival • apoptosis • cancer therapy Introduction TNF-related ligands can induce pleiotropic biological re- tumorigenesis. APRIL is a close sequence homologue of B sponses.
    [Show full text]
  • Characterisation of Chicken OX40 and OX40L
    Characterisation of chicken OX40 and OX40L von Stephanie Hanna Katharina Scherer Inaugural-Dissertation zur Erlangung der Doktorw¨urde der Tier¨arztlichenFakult¨at der Ludwig-Maximilians-Universit¨atM¨unchen Characterisation of chicken OX40 and OX40L von Stephanie Hanna Katharina Scherer aus Baunach bei Bamberg M¨unchen2018 Aus dem Veterin¨arwissenschaftlichenDepartment der Tier¨arztlichenFakult¨at der Ludwig-Maximilians-Universit¨atM¨unchen Lehrstuhl f¨urPhysiologie Arbeit angefertigt unter der Leitung von Univ.-Prof. Dr. Thomas G¨obel Gedruckt mit Genehmigung der Tier¨arztlichenFakult¨at der Ludwig-Maximilians-Universit¨atM¨unchen Dekan: Univ.-Prof. Dr. Reinhard K. Straubinger, Ph.D. Berichterstatter: Univ.-Prof. Dr. Thomas G¨obel Korreferenten: Priv.-Doz. Dr. Nadja Herbach Univ.-Prof. Dr. Bernhard Aigner Prof. Dr. Herbert Kaltner Univ.-Prof. Dr. R¨udiger Wanke Tag der Promotion: 27. Juli 2018 Meinen Eltern und Großeltern Contents List of Figures 11 Abbreviations 13 1 Introduction 17 2 Fundamentals 19 2.1 T cell activation . 19 2.1.1 The activation of T cells requires the presence of several signals 19 2.1.2 Costimulatory signals transmitted via members of the im- munoglobulin superfamily . 22 2.1.3 Costimulatory signals transmitted via members of the cy- tokine receptor family . 23 2.1.4 Costimulatory signals transmitted via members of the tumour necrosis factor receptor superfamily . 24 2.2 The tumour necrosis factor receptor superfamily . 26 2.2.1 The structure of tumour necrosis factor receptors . 26 2.2.2 Functional classification of TNFRSF members . 28 2.3 The tumour necrosis factor superfamily . 29 2.3.1 The structure of tumour necrosis factor ligands .
    [Show full text]
  • ©Ferrata Storti Foundation
    Malignant Lymphomas research paper Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas apoptosis in Burkitt’s lymphomas with loss of multiple pro-apoptotic proteins AZHAR HUSSAIN, JEAN-PIERRE DOUCET, MARINA I. GUTIÉRREZ, MANZOOR AHMAD, KHALED AL-HUSSEIN, DANIELA CAPELLO, GIANLUCA GAIDANO, KISHOR BHATIA Background and Objectives. Normal B-cells in the ger- nduction of cell death can result from signaling via minal center (GC) may be exposed to both tumor necro- external death receptors such as CD95/Fas and tumor sis factor-related apoptosis inducing ligand (TRAIL) and Inecrosis factor-related apoptosis-inducing ligand Fas-L. Whether abrogation of TRAIL apoptosis is a feature (TRAIL) receptors1-4 or it can result from exposure to in the genesis of B cell lymphomas of GC-phenotype is not chemicals, irradiation and serum starvation.5-7 Signal- known. We assessed the integrity of the TRAIL pathway in ing through external receptors activates the extrinsic Fas-resistant and Fas-sensitive Burkitt’s lymphomas (BLs). pathway8 headed by the apical caspases, caspase-8 and Design and Methods. Expression of TRAIL receptors caspase-10. On the other hand, death resulting from was determined by flow cytometry and Western blots. The chemotherapeutic agents appears to require exclusive- extent of apoptosis following exposure to TRAIL was mea- ly the intrinsic pathway9 involving the mitochondrial sured by annexin-V/propidium iodide dual staining. The release of death activators – cytochrome c and integrity of the Fas and TRAIL apoptotic pathways was Smac/Diablo, which in turn activate the caspase cas- determined by Western blotting to assess cleavage of cade led by caspase-9 via the apoptosome.10,11 While downstream caspases.
    [Show full text]
  • Targeting TRAIL-Rs in KRAS-Driven Cancer Silvia Von Karstedt 1,2,3 and Henning Walczak2,4,5
    von Karstedt and Walczak Cell Death Discovery (2020) 6:14 https://doi.org/10.1038/s41420-020-0249-4 Cell Death Discovery PERSPECTIVE Open Access An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer Silvia von Karstedt 1,2,3 and Henning Walczak2,4,5 Abstract Twenty-one percent of all human cancers bear constitutively activating mutations in the proto-oncogene KRAS. This incidence is substantially higher in some of the most inherently therapy-resistant cancers including 30% of non-small cell lung cancers (NSCLC), 50% of colorectal cancers, and 95% of pancreatic ductal adenocarcinomas (PDAC). Importantly, survival of patients with KRAS-mutated PDAC and NSCLC has not significantly improved since the 1970s highlighting an urgent need to re-examine how oncogenic KRAS influences cell death signaling outputs. Interestingly, cancers expressing oncogenic KRAS manage to escape antitumor immunity via upregulation of programmed cell death 1 ligand 1 (PD-L1). Recently, the development of next-generation KRASG12C-selective inhibitors has shown therapeutic efficacy by triggering antitumor immunity. Yet, clinical trials testing immune checkpoint blockade in KRAS- mutated cancers have yielded disappointing results suggesting other, additional means endow these tumors with the capacity to escape immune recognition. Intriguingly, oncogenic KRAS reprograms regulated cell death pathways triggered by death receptors of the tumor necrosis factor (TNF) receptor superfamily. Perverting the course of their intended function, KRAS-mutated cancers use endogenous TNF-related apoptosis-inducing ligand (TRAIL) and its receptor(s) to promote tumor growth and metastases. Yet, endogenous TRAIL–TRAIL-receptor signaling can be therapeutically targeted and, excitingly, this may not only counteract oncogenic KRAS-driven cancer cell migration, invasion, and metastasis, but also the immunosuppressive reprogramming of the tumor microenvironment it causes.
    [Show full text]
  • Differential Signaling Via Tumor Necrosis Factor-Associated Factors (Trafs) by CD27 and CD40 in Mouse B Cells
    Differential Signaling via Tumor Necrosis Factor-Associated Factors (TRAFs) by CD27 and CD40 in Mouse B Cells So-Youn Woo1*, Hae-Kyung Park1 and Gail A. Bishop2,3,4 Department of Microbiology1, College of Medicine, Ewha Womans University, Seoul 158-710, Korea, Department of Microbiology2, and Department of Internal Medicine3, The University of Iowa, Veterans Affairs Medical Center4, Iowa City, IA 52242 ABSTRACT Background: CD27 is recently known as a memory B cell marker and is mainly ex- pressed in activated T cells, some B cell population and NK cells. CD27 is a member of tumor necrosis factor receptor family. Like CD40 molecule, CD27 has (P/S/T/A) X(Q/E)E motif for interacting with TNF receptor-associated factors (TRAFs), and TRAF2 and TRAF5 bindings to CD27 in 293T cells were reported. Methods: To investigate the CD27 signaling effect in B cells, human CD40 extracellular domain containing mouse CD27 cytoplamic domain construct (hCD40-mCD27) was transfected into mouse B cell line CH12.LX and M12.4.1. Results: Through the stimulation of hCD40-mCD27 molecule via anti-human CD40 antibody or CD154 ligation, expression of CD11a, CD23, CD54, CD70 and CD80 were increased and secretion of IgM was induced, which were comparable to the effect of CD40 stimulation. TRAF2 and TRAF3 were recruited into lipid-enriched membrane raft and were bound to CD27 in M12.4.1 cells. CD27 stimulation, however, did not increase TRAF2 or TRAF3 degradation. Conclusion: In contrast to CD40 signaling pathway, TRAF2 and TRAF3 degradation was not observed after CD27 stimulation and it might contribute to prolonged B cell activation through CD27 signaling.
    [Show full text]
  • Mechanism CD40-Dependent Cytolytic − Novel CD154
    Vaccination Produces CD4 T Cells with a Novel CD154−CD40-Dependent Cytolytic Mechanism This information is current as Rhea N. Coler, Thomas Hudson, Sean Hughes, Po-wei D. of October 1, 2021. Huang, Elyse A. Beebe and Mark T. Orr J Immunol published online 21 August 2015 http://www.jimmunol.org/content/early/2015/08/20/jimmun ol.1501118 Downloaded from Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision http://www.jimmunol.org/ • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on October 1, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published August 21, 2015, doi:10.4049/jimmunol.1501118 The Journal of Immunology Vaccination Produces CD4 T Cells with a Novel CD154–CD40-Dependent Cytolytic Mechanism Rhea N. Coler,*,†,‡ Thomas Hudson,* Sean Hughes,* Po-wei D. Huang,* Elyse A. Beebe,* and Mark T. Orr*,† The discovery of new vaccines against infectious diseases and cancer requires the development of novel adjuvants with well-defined activities.
    [Show full text]
  • 3901.Full.Pdf
    Signaling through CD70 Regulates B Cell Activation and IgG Production Ramon Arens, Martijn A. Nolte, Kiki Tesselaar, Bianca Heemskerk, Kris A. Reedquist, René A. W. van Lier and This information is current as Marinus H. J. van Oers of September 23, 2021. J Immunol 2004; 173:3901-3908; ; doi: 10.4049/jimmunol.173.6.3901 http://www.jimmunol.org/content/173/6/3901 Downloaded from References This article cites 43 articles, 26 of which you can access for free at: http://www.jimmunol.org/content/173/6/3901.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 23, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Signaling through CD70 Regulates B Cell Activation and IgG Production Ramon Arens,1*† Martijn A. Nolte,1*† Kiki Tesselaar,2† Bianca Heemskerk,3† Kris A. Reedquist,† Rene´A. W. van Lier,† and Marinus H.
    [Show full text]